Global Influenza Market Surges Amid Diagnostic Innovation
BOSTON, July 15, 2025 /PRNewswire/ — According to the latest study from BCC Research, 'The Global Influenza Market' is expected to grow from $9.0 billion in 2024 to $12.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2029.
This report offers a well-rounded analysis of the global influenza market, covering both historical and current trends. It examines the disease burden, vaccine coverage, and market dynamics across the major regions of North America, Europe, and Asia-Pacific. The market is segmented into vaccines (inactivated and live-attenuated), therapeutics, and diagnostics (rapid and conventional tests). It also highlights leading products, clinical trials, new approvals, and emerging technologies. Additionally, the report profiles major companies and outlines their strategies, while providing growth forecasts and opportunities for each product segment in major regions.
This report is particularly relevant today because public health systems and healthcare providers need to prepare for a potential rise in influenza cases. It helps forecast how many people could need to seek medical care, what quantity of drugs or vaccines will be needed, and which resources such as hospital beds or antivirals might be stretched. For pharmaceutical companies, the report is crucial for identifying areas with strong demand and adjusting their production or distribution strategies accordingly to ensure the timely and efficient delivery of flu vaccines and treatments.
The factors driving the market's growth include:
Faster Testing Technologies: New rapid tests and molecular tools help detect flu viruses quickly and accurately. This allows doctors to treat patients sooner and helps prevent the spread of the virus, boosting demand for diagnostics.
Government Support: Governments are funding research and speeding up approvals for new flu treatments and tests. This support encourages innovation and helps bring new products to market faster.
More Vaccine Awareness: People are more aware of the importance of flu shots, especially after recent global health events. Public campaigns and easier access to vaccines have led to higher vaccination rates.
Request a sample copy of the global influenza market report.
Report Synopsis
Report Metric
Details
Base year considered
2023
Forecast period considered
2024-2029
Base year market size
$8.4 billion
Market size forecast
$12.8 billion
Growth rate
CAGR of 7.2% for the forecast period of 2024-2029
Segments covered
Vaccines, Therapeutics, Diagnostics, and Region
Regions covered
North America, Asia-Pacific, Europe, Rest of the World (includes South America, and the Middle East and Africa)
Countries covered
U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, China, Australia,
Market drivers
• Development of rapid tests and molecular technologies.
• Government support and funding for novel therapies and diagnosis.
• Rising public awareness of the need for flu vaccines.
Interesting facts:
GSK Begins Early Flu Vaccine Distribution: Ahead of the 2024–2025 flu season, GSK plc has started shipping its trivalent influenza vaccines across the U.S. This rollout follows the FDA's approval of the lot release and licensing, ensuring timely availability at pharmacies and healthcare facilities.
Sanofi's Dual Vaccine Candidates Fast-Tracked: In December 2024, the FDA granted Fast Track designation to two of Sanofi's combination vaccine candidates designed to protect individuals 50 and older from influenza and COVID-19. These candidates merge two already approved vaccines, each proven effective and well-tolerated in clinical trials.
FluMist, the First Self-Administered Flu Vaccine Approved in the U.S.: In a groundbreaking move, the FDA approved FluMist in 2024 as the only self-administered influenza vaccine available in the U.S. Adults up to age 49 can now use this needle-free nasal spray on their own, while parents or caregivers can administer it to children 2 to 17. The approval was based on a comprehensive submission, including a usability study confirming that adults could safely administer the vaccine to themselves or others within the eligible age range.
Emerging startups
Ansun BioPharma
Virolock Technologies
Vaxart
The report addresses the following questions:
What is the projected size and growth rate of the market?–The global influenza market was valued at $8.4 billion in 2023 and is expected to reach $12.8 billion by the end of 2029. The market is expected to grow at a CAGR of 7.2% from 2024 to 2029.
What factors are driving the growth of the market?– Factors that are driving the market's growth are the development of rapid tests and molecular technologies, government support and funding for novel therapies and diagnosis, and rising public awareness about flu vaccines.
Which market segments are covered in the report?– The market size for influenza is categorized into three product segments: Vaccines, Therapeutics, and Diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. The diagnostics, market is divided into rapid tests and conventional lab tests.
Which product segment will be dominant through 2029?– Vaccines will be the dominant market segment through 2029.
Which region has the highest market share?–The North American market for influenza was valued at $4.2 billion in 2023 and is projected to reach $6.3 billion in 2029, at a CAGR of 7.3% during the forecast period.
Market leaders include:
ABBOTT
ASTRAZENECA
BECTON DICKINSON
BIOCRYST PHARMACEUTICALS INC.
CSL
DAIICHI SANKYO CO. LTD.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC.
HOLOGIC INC.
QUIDELORTHO CORP.
SANOFI
SEKISUI DIAGNOSTICS
THERMO FISHER SCIENTIFIC INC.
VIATRIS INC.
Related reports:
Global Markets for Vaccine Technologies: This report provides an in-depth look at the human vaccine industry, focusing on key trends, market drivers and restraints, and the impact of new technologies and competition. It covers vaccine types, including pneumococcal, HPV, MMR, and influenza, but excludes animal vaccines. The study also examines R&D spending, product launches, and strategic moves like mergers, acquisitions and collaborations. It offers insights for stakeholders such as manufacturers, researchers, healthcare providers, and government agencies, with detailed regional analysis to support market expansion efforts.
Purchase a copy of the report direct from BCC Research.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@bccresearch.comPhone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo – https://mma.prnewswire.com/media/2183242/5416385/BCC_Research_Logo.jpg
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
10 hours ago
- Malaysian Reserve
United Breast Cancer Foundation Expands Support in the Southeast with Major Mattress & Pink Bag Event in Tallahassee, FL
130 Breast Cancer Patients and Survivors Served During Five-Day Distribution of Donated Essentials TALLAHASSEE, Fla., July 22, 2025 /PRNewswire/ — United Breast Cancer Foundation (UBCF) hosted a multi-day Mattress & Pink Bag Event at Governor's Square Mall in Tallahassee, FL, from June 26th through the 30th. The impactful event provided essential support to 130 breast cancer patients and survivors, distributing more than $1.45 million in donated goods including therapeutic mattresses, clothing, shoes, personal care products, household items, toys, and children's items and more. Attendees came from Florida and many surrounding states, with some coming from as far as Ohio, Texas, Pennsylvania and Maine —underscoring the event's wide-reaching impact. This event marked UBCF's first time offering the Mattress & Pink Bag Program in a multi-day format. The expanded schedule increased accessibility, reduced wait times, and allowed for deeper engagement with participants. The days were filled with gratitude, hugs, tears, and connection—a meaningful experience for recipients, volunteers, and staff alike. Event attendee, Alisa wrote in to share her gratitude, 'Dear UBCF Team, I wanted to personally thank you for the generous gifts I received at the Florida Mattress & Pink Bag Shopping Event. I didn't want to miss the chance to reach out and express how much it truly means to me to go to sleep more comfortably at night without the aches and pains I experienced before getting my new mattress. The event was not only a beautiful experience, but also a powerful reminder that kindness and support still exist in 'abundance'. Receiving the gifts made me feel seen, supported, and genuinely cared for and I am so grateful for everything I received. Thank you again for all that you do for breast cancer patients and survivors. Your work makes a real difference, and I'm incredibly thankful to be one of the people impacted by your love and compassion. With heartfelt appreciation, Alisa' Kara shared this beautiful message, 'I wanted to be sure I reached out to say thank you a million times for the amazing experience you brought to Tallahassee. The mattress is the best mattress I have ever had in my life, and that dern pillow we got to pick out is insane. I have never loved a pillow so much lol. Everything was amazing especially the experience of being around others in a similar situation as myself. Thank you again and many blessings.' High-quality sleep is critical for breast cancer recovery. A 2025 study published in BMC Cancer reported that sleep disturbances are among the strongest predictors of reduced quality of life in breast cancer patients undergoing chemotherapy. Additionally, the American Academy of Sleep Medicine found that better sleep efficiency was linked to significantly longer survival times—women with advanced breast cancer who slept well lived twice as long on average. Community support also plays a powerful role in survivorship. Research has shown that patients who feel supported and heard experience lower levels of depression, pain, and inflammation and improved long-term quality of life. Events like this are especially important in states like Florida, where breast cancer is a serious public health concern. It is the most commonly diagnosed cancer among women in Florida, with over 19,000 new cases diagnosed each year. Florida also faces persistent disparities in late-stage diagnoses—particularly in underserved communities. A statewide analysis found that patients from high-poverty rural areas had 31% higher odds of being diagnosed at a late stage compared to patients from low-poverty urban areas. Patients in high-poverty areas often face barriers such as limited access to healthcare, financial challenges, lower awareness of breast cancer symptoms, and systemic healthcare inequities—all of which contribute to delays in screening and diagnosis. This makes outreach and support events like UBCF's Mattress & Pink Bag Event vital to helping bridge these gaps. UBCF extends its sincere gratitude to the community partners who made this event possible. Special thanks to Governor's Square Mall for generously donating the event space, Whole Foods Market for providing dedicated volunteers who brought compassion, and People Ready for supplying reliable staffing support throughout the multi-day event. Their contributions were essential to the event's success and the meaningful experiences shared by all who attended. UBCF's next Mattress & Pink Bag Event will take place in Jonesboro, Arkansas, from October 16–19, 2025. As always, the event is free to qualified breast cancer patients and survivors. To learn more about UBCF's programs, to apply for assistance, or to make a donation, visit About UBCF United Breast Cancer Foundation is a non-profit founded in 2000 with a mission to make a positive difference in the lives of those impacted by breast cancer. UBCF is committed to gifting helpful and supportive donated items, providing financial grants to those in need, and funding breast health and wellness services focused on education, screening, treatment, recovery, overall wellness, and beyond. The platinum rated, 4-star charity offers numerous life-supporting patient and family programs available to women, men, and families nationwide. Tax-deductible contributions (consult your tax advisor) may be made towards UBCF's programs. UBCF accepts contributions through Donor Advised Funds and vehicle and property donations as well.
Malaysian Reserve
21 hours ago
- Malaysian Reserve
Medunik USA expands Siklos® (hydroxyurea) coverage under Medicaid Programs to 37 states
PRINCETON, N.J., July 22, 2025 /PRNewswire/ – Medunik USA, a specialty pharmaceutical company dedicated to providing rare disease patients with access to orphan drugs and part of Duchesnay Pharmaceutical Group (DPG), winner of the 2024 Life Sciences Innovation Award by ADRIQ, is pleased to announce that public reimbursement for Siklos® (hydroxyurea) under Medicaid Programs is now available in 37 states, with 13 states including it on their Preferred Drug List, while 24 states offer it with limited, or no, restrictions. This important milestone for Medunik USA allows broader access to this essential medicine, benefiting patients suffering from sickle cell disease (SCD). Siklos® has been used worldwide to treat SCD for over 15 years and was approved by the FDA for use in the USA in 2017. This medicine is the only hydroxyurea (HU)-based therapeutic option that offers both flexible dosing and administration, giving patients and caregivers more control over managing their care and shaping a treatment routine that works for them. Patients can choose the best way to take Siklos®, whether by swallowing it whole or split based on the dose, or dissolving it in a small amount of water. Siklos® is the only FDA-approved dissolvable formulation of hydroxyurea that reduces painful crises and blood transfusions for sickle cell patients aged 2 years and older. Siklos® has a BOXED WARNING regarding Low Blood Cell Count and Cancer. The most common side effects of Siklos® in children include: infections and low white blood cells, and in adults include: infections, headache, and dry skin. 'We are proud to see increased coverage for this important therapy, which represents a significant step forward in the standard of care for patients with sickle cell disease. Siklos® provides patients with options on how to best take their HU treatment,' said Tanya Carro, Executive Vice President, U.S. Entities. 'With fewer SCD treatment options currently available, it is even more important to empower patients to stay on therapy in a way that fits their lives. That's what drives long-term adherence and meaningful health outcomes.' Sickle cell anemia is the most common inherited blood disorder, resulting in the production of abnormal hemoglobin, known as hemoglobin-S, responsible for the sickling of red blood cells. This disease affects nearly 100,000 Americans, decreases life expectancy by 25 to 30 years, induces significant morbidity and, may therefore, reduce quality of life1,2. Most of those affected are of African ancestry; a minority are of Hispanic or southern European, Middle Eastern or Asian Indian descent3. Committed to improving the lives of people living with rare disorders, Medunik USA strives to remove the logistical barriers and to broaden reimbursement pathways to empower patients with SCD and their caregivers. Medunik USA supports patient access by offering a robust assistance program that includes educational resources and savings programs. For more information please visit: . INDICATION AND IMPORTANT SAFETY INFORMATION SIKLOS is a prescription medicine that is used to reduce the frequency of painful crises and reduce the need for blood transfusions in adults and children, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises. It is not known if SIKLOS is safe and effective in children less than 2 years of age. IMPORTANT SAFETY INFORMATION BOXED WARNING: LOW BLOOD CELL COUNT and CANCERSee Full Prescribing Information for complete Boxed Warning. Low blood cell counts are common with SIKLOS, including low red blood cells, white blood cells, and platelets, and can be severe and life threatening. If your white blood cell count becomes very low, you are at increased risk for infection. Your healthcare provider will check your blood cell counts before and every 2 weeks during treatment with SIKLOS. Your healthcare provider may change your dose or tell you to stop taking SIKLOS if you have low blood cell counts. Tell your healthcare provider right away if you get any of the following symptoms: fever or chills; shortness of breath; body aches; unusual headache; feeling very tired; bleeding or unexplained bruising. Cancer. Some people have developed cancer, such as leukemia and skin cancer, after taking SIKLOS for a long time. Your healthcare provider will check you for cancer. You should protect your skin from the sun using sunblock, hats, and sun-protective clothing. WHAT IS THE MOST IMPORTANT INFORMATION YOU SHOULD KNOW ABOUT SIKLOS? SIKLOS can harm your unborn baby. For females taking SIKLOS who can become pregnant: You should talk with your healthcare provider about the risks of SIKLOS to your unborn baby. You should use effective birth control during treatment with SIKLOS and for at least 6 months after treatment with SIKLOS. Your healthcare provider will perform a pregnancy test before you start treatment with SIKLOS. Tell your healthcare provider right away if you become pregnant or think you may be pregnant. For males taking SIKLOS: SIKLOS can affect your sperm. If you have a female sexual partner who can become pregnant, you should use effective birth control during treatment with SIKLOS and for at least 6 months after treatment. SIKLOS may cause fertility problems in males. Talk to your healthcare provider if this is a concern for you. You should talk with your healthcare provider about the risks of SIKLOS to your unborn baby. You should use effective birth control during treatment with SIKLOS and for at least 6 months after treatment with SIKLOS. Your healthcare provider will perform a pregnancy test before you start treatment with SIKLOS. Tell your healthcare provider right away if you become pregnant or think you may be pregnant. WHO SHOULD NOT TAKE SIKLOSDo not take SIKLOS if you are allergic to hydroxyurea or any of the ingredients in SIKLOS. See the Medication Guide for a list of the ingredients in SIKLOS. WHAT SHOULD YOU TELL YOUR HEALTH CARE PROVIDER BEFORE TAKING SIKLOS?Tell your healthcare provider about all of your medical conditions, including if you: have kidney problems or are receiving hemodialysis have liver problems have human immunodeficiency virus (HIV) or take HIV medicines. Taking SIKLOS with certain HIV medicines can cause serious reactions and may lead to death. have increased levels of uric acid in your blood (hyperuricemia) have a history of receiving interferon therapy or are currently receiving interferon therapy have leg wounds or ulcers plan to receive any vaccinations. You should not receive 'live vaccines' during treatment with SIKLOS. are pregnant or plan to become pregnant. See 'What is the most important information I should know about SIKLOS?' are breastfeeding or plan to breastfeed. It is not known if SIKLOS can pass into your breast milk. Do not breastfeed during treatment with SIKLOS. are using a continuous glucose monitor (CGM) to test your blood glucose. Talk to the healthcare provider that prescribed your CGM about whether it is safe to use while you are taking SIKLOS. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. WHAT ARE THE POSSIBLE SIDE EFFECTS OF SIKLOS?SIKLOS may cause serious side effects, including: See 'What is the most important information I should know about SIKLOS?' Skin ulcers, including leg ulcers, and death of skin tissue (gangrene) have happened in people who take SIKLOS. This has happened most often in people who receive interferon therapy or have a history of interferon therapy. Your healthcare provider will decrease your dose or stop treatment with SIKLOS if you develop any skin ulcers. Enlarged red blood cells (macrocytosis). Macrocytosis is common in people who take SIKLOS and can make it difficult to detect a decrease of folic acid. Your healthcare provider may prescribe a folic acid supplement for you. Hemolytic Anemia, the fast breakdown of red blood cells, has happened in people who take SIKLOS. Tell your healthcare provider I you develop yellowing of your skin (jaundice) or blood in your urine. Your healthcare provider may do blood tests if you have persistent or worsening anemia not related to sickle cell anemia. The most common side effects of SIKLOS in children include: infections and low white blood cells. The most common side effects of SIKLOS in adults include: infections, headache, and dry skin. These are not all the possible side effects of SIKLOS. You are encouraged to report negative side effects of prescription drugs to the FDA at or 1-800-FDA-1088. Please read the Full Prescribing Information, including Boxed Warning, Medication Guide and Instructions for Use, at ABOUT MEDUNIK USA Based in Princeton, New Jersey, Medunik USA is part of Duchesnay Pharmaceutical Group and works to improve the health and quality of life of Americans living with rare diseases by making orphan drug therapies available in the United States. Through its strategic partnerships, Medunik USA develops and provides Americans suffering from rare disease with access to orphan drugs that are not currently available in the U.S. Medunik USA makes critical medications to treat rare diseases available to American patients who might not otherwise have access to these medications. For more information about Medunik USA, please visit Follow us on LinkedIn. ABOUT DUCHESNAY PHARMACEUTICAL GROUP Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries. DPG is one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate its growth to become an anchor firm in the Canadian economy. DPG is the winner of the 2024 Life Sciences Innovation Award by ADRIQ, the Association for the Development of Research and Innovation of Quebec, which recognizes DPG's healthy workplace culture and commitment to pharmaceutical innovation, while DPG president Éric Gervais is the recipient of the 2024 Bernard-Landry Award by ADRIQ which acknowledges his impactful leadership on Quebec's research and innovation ecosystem. DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations. For more information, please visit Follow us on LinkedIn. References: 1. Platt OS et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. The New England Journal of Medicine 330, 1639-1644, doi:10.1056/NEJM199406093302303 (1994). 2. McGann PT and Ware RE, Hydroxyurea therapy for sickle cell anemia. Expert opinion on drug safety 14, 1749-1758, doi:10.1517/14740338.2015.1088827 (2015). 3. National Heart, Lung, and Blood Institute, National Institutes of Health, Sickle Cell Disease,
Malaysian Reserve
a day ago
- Malaysian Reserve
Swoop Appoints Sara Michael as EVP of Content at MyHealthTeam
NEW YORK, July 21, 2025 /PRNewswire/ — Swoop, a leader in AI-driven, data-powered, and privacy-compliant omnichannel healthcare marketing, today announced the appointment of Sara Michael as Executive Vice President of Content at MyHealthTeam, reinforcing the company's commitment to delivering trusted, medically verified information and meaningful engagement for people living with chronic and rare conditions. A seasoned leader in health journalism and digital content strategy, Sara most recently served at Dotdash Meredith, where she led editorial and business strategy for health brands including Verywell Health, Verywell Mind, and She brings deep expertise in developing high-impact content experiences that prioritize patient needs while aligning with business growth. Sara will lead a unified content organization spanning editorial development, design, video, content operations, and copy editing. Her leadership is instrumental in scaling MyHealthTeam's reach, quality, and impact as the largest opt-in patient community in the U.S., now spanning more than 60 condition-specific social networks. 'I've long admired the mission and impact of MyHealthTeam. I'm thrilled to join at such an exciting time, alongside such a passionate team, all focused on supporting people living with chronic conditions,' said Sara. 'This role brings together my passion for health journalism and innovation with a mission that truly matters — empowering people to take control of their health by connecting with others and accessing reliable information they can trust.' As EVP of Content, Sara will drive initiatives to: Expand the reach and depth of content across all MyHealthTeam platforms Integrate medically reviewed education and patient insights into all engagement Elevate storytelling to reflect the diverse experiences of chronic condition communities Enable brand partners to deliver relevant, privacy-safe messages that align with patient needs 'Sara's arrival marks a major step forward in scaling our patient-first model,' said Eric Peacock, Chief Patient Officer of Swoop and Co-founder and President of MyHealthTeam. 'Her leadership will accelerate our ability to deliver authentic, high-quality content at scale — meeting patients where they are, while ensuring our brand partners can engage in ways that are respectful, useful, and effective.' About SwoopSwoop is a leading provider of AI-driven, precision healthcare omnichannel solutions dedicated to protecting consumer privacy and improving patient outcomes. By prioritizing privacy and compliance, Swoop delivers industry-leading audience segments, 100% MLR-approved conversational AI agents, and now a leading opted-in patient social network in the U.S. through its acquisition of MyHealthTeam. Swoop's solutions drive meaningful patient and provider engagement, optimal conversion, and measurable increases in Rx lift across the patient health journey. About MyHealthTeamMyHealthTeam, a Swoop company, is the creator of one of the largest and highly engaged patient social networks in healthcare, offering more than 62 condition-specific communities to support patients with chronic and rare conditions. These platforms empower millions of opted-in patients nationwide to connect, share resources, and access medically verified information to better manage their health.
